Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

October 9, 2026

Study Completion Date

October 9, 2029

Conditions
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedLarge B-Cell Lymphoma With IRF4 RearrangementPrimary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeRecurrent Aggressive B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRecurrent Intravascular Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent T-Cell/Histiocyte-Rich Large B-Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Aggressive B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 RearrangementsRefractory Intravascular Large B-Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell LymphomaRefractory T-Cell/Histiocyte-Rich Large B-Cell LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Chimeric Antigen Receptor T-Cell Therapy

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Zanubrutinib

Given PO

Trial Locations (2)

53226

Medical College of Wisconsin, Milwaukee

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER